Endometriosis - Pipeline Insight, 2024

This “Endometriosis - Pipeline Insight, 2024,” report provides comprehensive insights about 18+ companies and 25+ pipeline drugs in Endometriosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Endometriosis Understanding

Endometriosis: Overview

Endometriosis is a disease in which the endometrium (the tissue that lines the inside of the uterus or womb) is present outside of the uterus. Endometriosis most commonly occurs in the lower abdomen or pelvis, but it can appear anywhere in the body. Symptoms of endometriosis include lower abdominal pain, pain with menstrual periods, pain with sexual intercourse, and difficulty getting pregnant. On the other hand, some women with endometriosis may not have any symptoms at all. Approximately 10% of reproductive-aged women have endometriosis. However, the true prevalence is unknown since the diagnosis requires laparoscopy (a surgery where a doctor looks in the abdomen with a camera through the belly button) to visualize and biopsy endometriosis lesions. The most conservative therapy for endometriosis is with medications. Non-steroidal anti-inflammatory medications, like ibuprofen, may help with the pain associated with endometriosis. Medications that control a woman’s hormones may also help with endometriosis pain. Surgery can diagnose endometriosis, and it can also treat endometriosis via removal (excision) or burning (fulguration) of endometriosis lesions. With surgery, removal of scar tissue can alleviate pain and relocate the ovaries and fallopian tubes to their normal position in the pelvis.

Endometriosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometriosis pipeline landscape is provided which includes the disease overview and Endometriosis treatment guidelines. The assessment part of the report embraces, in depth Endometriosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometriosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Endometriosis R&D. The therapies under development are focused on novel approaches to treat/improve Endometriosis.

Endometriosis Emerging Drugs Chapters

This segment of the Endometriosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endometriosis Emerging Drugs

Linzagolix: ObsEvaObsEva is currently advancing linzagolix, a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of endometriosis-associated pain. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately dose-dependently reducing estrogen production by the ovaries. Through previously reported results from linzagolix and sophisticated pharmacological modelling, it has been established that maintaining estradiol within a specific target range provides the optimal balance between reducing symptoms while mitigating bone density loss associated with excessive estradiol suppression. In 2015, ObsEva in-licensed Linzagolix from Kissei Pharmaceutical Co., which had completed several Phase 2a clinical trials in Japan.Currently, the drug is being evaluated in Phase III clinical trial evaluation for the treatment of Endometriosis.

Relugolix: Myovant SciencesRelugolix Combination Tablet consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the treatment of endometriosis and for the prevention of pregnancy. Phase III clinical program for endometriosis consisted of two multinational, replicate pivotal clinical studies (SPIRIT 1 and SPIRIT 2) of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis. In January 2021, Myovant Sciences and Pfizer Inc. announced that the Phase III SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss.

Endometriosis: Therapeutic Assessment

This segment of the report provides insights about the different Endometriosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Endometriosis

There are approx. 18+ key companies which are developing the therapies for Endometriosis. The companies which have their Endometriosis drug candidates in the most advanced stage, i.e. Phase III include, ObsEva.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endometriosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endometriosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometriosis drugs.

Endometriosis Report Insights

• Endometriosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Endometriosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Endometriosis drugs?
• How many Endometriosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometriosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Endometriosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Endometriosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ObsEva SA
• Myovant Sciences
• Dexa Medica Group
• Ferring Pharmaceuticals
• Merck Sharp & Dohme Corp.
• Bayer
• BCI Pharma
• Jiangsu HengRui Medicine Co., Ltd.
• Forendo Pharma
• Mitsubishi Tanabe Pharma Corporation
• Chugai Pharmaceutical
• Nippon Shinyaku
• Celmatix
• Camurus
• Enteris BioPharma
• Viramal

Key Products

• AMY 109
• BOL-DP-o-08

Research programme: macrophage colony stimulating factor receptor 1 inhibitors- BAY 1158061

• TAK-385
• FOR 6219
• SHR 7280
• Leuprorelin oral
• MT-2990
• BAY2328065

This product will be delivered within 1-3 business days.